I-Mab reported its full year 2024 financial results, highlighting a strong financial position with $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024. This cash balance is expected to provide a runway into 2027, funding the company through anticipated clinical readouts.
The company noted continued positive momentum in its givastomig Phase 1b combination trial in first-line gastric cancer. Topline dose escalation data (n=17) for this study are expected in the second half of 2025.
Enrollment in the first givastomig Phase 1b dose expansion cohort was completed ahead of schedule, and momentum continues in the second expansion cohort. This accelerated progress underscores the efficient execution of I-Mab's clinical development strategy for its lead program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.